Psoriatic Arthritis
Conference Coverage
Etanercept bests methotrexate for PsA; combo adds little benefit
Conference Coverage
Over one-third of psoriasis patients have PsA
And more top psoriasis posters from the Las Vegas Dermatology Seminar
News
FDA approves adalimumab biosimilar Hyrimoz
Hyrimoz is the third adalimumab biosimilar approved by the FDA.
From the Journals
Psoriasis adds to increased risk of cardiovascular procedures, surgery in patients with hypertension
The results suggest that hypertensive patients and psoriasis have “earlier and more aggressive disease progression of hypertension.”
Conference Coverage
ACR readies first-ever guidelines on managing reproductive health in rheumatology
CHICAGO – “One of the key messages of the guidelines is that patients really do want to discuss these topics with their rheumatologist,” said Dr....
From the Journals
Flu vaccination lags among patients with psoriasis
Dermatologists could play a key role in encouraging flu vaccines in this vulnerable population.
Conference Coverage
IL inhibitor options move psoriasis treatment forward
Long-term data continue to support the safety and effectiveness of IL-17 and IL-23 inhibitor drugs.
From the Journals
Adalimumab safety update finds no new signals
The new integrated analysis includes safety data from five clinical trials that were not included in the analysis from 2009.
From the Journals
No evidence of subclinical axial involvement seen in skin psoriasis
Patients with longstanding psoriasis without peripheral or axial inflammation are unlikely to have subclinical involvement of the sacroiliac joint...
Opinion
Pregnancy registries are a valuable resource
Latest News
Novel oral agent shows unprecedented efficacy in psoriasis
PARIS – Selective tyrosine kinase 2 inhibitor reached a 75% PASI 75 response rate in moderate to severe psoriasis at 12 weeks.